RPE65 and Leber congenital amaurosis: Lessons learned from early gene therapy studies for Leber congenital amaurosis (LCA) due to biallelic pathogenic variants in RPE65 gene highlight the importance of natural history information in patient selection and choosing the useful outcome measures to best interpret results of clinical treatment trials.36